Sickle Cell Market Report
The Global Sickle Cell Market on the Global Sickle Cell Market is segmented By Therapy (Bone Marrow Transplant, Medications, Blood Transfusion, Gene Therapy), By End-User (Hospital, Clinic, Home Healthcare), and Region. This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Sickle Cell market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
The Global Sickle Cell Market on the Global Sickle Cell Market is segmented By Therapy (Bone Marrow Transplant, Medications, Blood Transfusion, Gene Therapy), By End-User (Hospital, Clinic, Home Healthcare), and Region. <...
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
The Global Sickle Cell Market is estimated to grow from USD xx million in 2020 to USD xx million by 2026 at a healthy CAGR of x% during the forecast period.
Figure: Global Sickle Cell Market Size, 2020-2026 (USD Million)
Sickle cell anemia is defined as an inherited red blood cell disorder in which the number of healthy red blood cells that carry oxygen throughout the body is not sufficient. The red blood cells are shaped like sickles or crescent moons in the person having sickle cell disease. These cells can get stuck in the small blood vessels and thus, slow or block blood flow and oxygen.
Key players operating in the global Sickle Cell market are-
The global market growth is primarily driven by the increasing prevalence of sickle cell traits among patients.
Based on end user, the market has been divided into hospital, clinic and home healthcare.
The market in North America accounted for the largest share in 2020 and is projected to register significant growth during the review period.
The covid-19 outbreak posed significant challenges to the health care system across geographies. It affected the growth of the sickle cell market negatively as patients postponed their appointments due to a rapid surge in covid-19 cases across geographies. Also, supply chain disruptions due to the imposition of lockdown affected the market growth further.
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
Bluebird bio, Inc. (The U.S), Eli Lilly and Company (The U.S), Gilead Sciences, Inc. (The U.S), Merck & Co., Inc. (The U.S), Novartis International AG (Switzerland), Sanofi S.A. (France), Baxter International Inc. (The U.S), Bristol-Myers Squibb (The U.S), Global Blood Therapeutics (The U.S), Johnson & Johnson (The U.S), Mast Therapeutics (The U.S) and Pfizer, Inc. (The U.S) are among the key players in the sickle cell market.
North America accounted for the largest share in 2020 and is projected to register significant growth.
Asia-pacific is expected to register the fastest growth rate in the sickle cell market in the coming years.
The clinic segment is expected to register the highest growth in the sickle cell market during the review period.
Increasing prevalence of sickle cell traits among patients, increasing clinical trials using various therapies are the factors driving the growth of sickle cell market.
Sickle cell distributors, Sickle cell suppliers, Sickle cell manufacturers, Logistics organizations, Government bodies are the target audience in the sickle cell market.